Skip To Main Content
Cameron DA on Muck Rack

Cameron DA

As seen in: Nature, PeerJ
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Cameron DA’s profile

Articles by Cameron DA

Analysis of factors influencing the pathological complete remission (ipCR) in patients with internal mammary lymph node metastasis after neoadjuvant chemotherapy

|
By Cameron DA, Kim HJ, Lee SW, Antonio BS
| PeerJ
Lymphatic drainage in the breast mainly occurs through the axillary and internal mammary lymph nodes. The ipsilateral ALN drains 75% of the lymph of the breast, while the remaining 25% of the lymph is drained from the IMLNs. Although the IMLNs are defined as regional nodes similar to the ALNs, previous studies have shown that BC cases with IMLN metastasis have a worse prognosis compared to cases involving metastasis to the ALNs (Madsen et al., 2015). Noguchi et al.
Open in Who Shared Issue with article?

Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

|
By Cameron DA, Joharatnam-Hogan N, Cafferty FH, Kynaston HG
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (632) Issue with article?

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

|
By Kunkler Ih, Williams LJ, Cameron DA, Jack WJL
| nlm.nih.gov
N Engl J Med. Display options Format doi: 10.1056/NEJMoa2207586. Affiliation 1 From the University of Edinburgh (I.H.K., L.J.W., D.A.C., J.M.D.) and Western General Hospital (W.J.L.J.) - both in Edinburgh.
Open in Who Shared Issue with article?

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

|
By O'Byrne K, O'Byrne KJ, Aapro MS, Cameron DA
| Nature Verified
This phase Ib study evaluated afatinib plus vinorelbine in patients with advanced solid tumours overexpressing epidermal growth factor receptor (EGFR) and/or human EGFR 2 (HER2). Maximum tolerated doses (MTDs) were determined for afatinib (20, 40 or 50?mg, once daily) combined with standard intravenous vinorelbine (part A; 25?mg?m?2 per week) or oral vinorelbine (part B; 60?mg?m?2 per week, increased to 80?mg?m?2 per week at week 3).
Open in Who Shared Issue with article?
Show More